These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28600702)

  • 21. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
    Naidu Y; Chaudhuri KR
    Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia.
    Fanciulli A; Assogna F; Caltagirone C; Spalletta G; Pontieri FE
    Aging Clin Exp Res; 2013 Oct; 25(5):601-3. PubMed ID: 24018606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of rotigotine on Parkinson's disease-related sleep disturbances.
    Antonini A; Calandrella D; Merello M; Koutsikos K; Pilleri M
    Expert Opin Pharmacother; 2013 Dec; 14(18):2571-80. PubMed ID: 24138154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hiccups associated with dopamine agonists in Parkinson disease.
    Sharma P; Morgan JC; Sethi KD
    Neurology; 2006 Mar; 66(5):774. PubMed ID: 16534128
    [No Abstract]   [Full Text] [Related]  

  • 26. Rotigotine adverse effects affecting patient's sexual partner.
    Hedera P
    Clin Neuropharmacol; 2010; 33(1):46-7. PubMed ID: 20124785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compulsive drumming induced by dopamine agonists in Parkinson's disease: Another aspect of punding.
    Vitale C; Trojano L; Barone P; Errico D; Agosti V; Sorrentino G; Grossi D; Santangelo G
    Behav Neurol; 2013 Jan; 27(4):559-62. PubMed ID: 23242361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study.
    Timmermann L; Oehlwein C; Ransmayr G; Fröhlich H; Will E; Schroeder H; Lauterbach T; Bauer L; Kassubek J
    Postgrad Med; 2017 Jan; 129(1):46-54. PubMed ID: 27883297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine agonist induced compulsive eating behaviour in a Parkinson's disease patient.
    Khan W; Rana AQ
    Pharm World Sci; 2010 Apr; 32(2):114-6. PubMed ID: 20039208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system.
    Raison-Peyron N; Guillot B
    Contact Dermatitis; 2016 Aug; 75(2):121-2. PubMed ID: 27385523
    [No Abstract]   [Full Text] [Related]  

  • 32. An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease.
    Wang Y; Yang YC; Lan DM; Wu H-; Zhao ZX
    Sleep Breath; 2017 May; 21(2):319-325. PubMed ID: 27726069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of transdermal rotigotine in a patient with advanced Parkinson's disease and dysphagia.
    Christie J
    Palliat Med; 2007 Mar; 21(2):163-4. PubMed ID: 17443935
    [No Abstract]   [Full Text] [Related]  

  • 34. Tramadol-induced hiccups: a case-noncase study in the European pharmacovigilance database.
    García M; Lertxundi U; Aguirre C
    Ther Adv Drug Saf; 2021; 12():20420986211021230. PubMed ID: 34211690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Local effects of transdermal treatment with rotigotine].
    Bermejo PE; Zea MA; Alba-Alcántara L; Ruiz-Huete C
    Rev Neurol; 2013 Apr; 56(7):359-62. PubMed ID: 23520004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis.
    Antonini A; Chaudhuri KR; Boroojerdi B; Asgharnejad M; Bauer L; Grieger F; Weintraub D
    Eur J Neurol; 2016 Oct; 23(10):1556-65. PubMed ID: 27425586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Night-time use of rotigotine in advanced Parkinson's disease.
    Canesi M; Mariani CB; Isaias IU; Pezzoli G
    Funct Neurol; 2010; 25(4):201-4. PubMed ID: 21388580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease.
    Fedorova NV; Chigir' IP
    Neurosci Behav Physiol; 2007 Jul; 37(6):539-46. PubMed ID: 17657423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
    Timmermann L; Asgharnejad M; Boroojerdi B; Dohin E; Woltering F; Elmer LW
    Expert Opin Pharmacother; 2015; 16(10):1423-33. PubMed ID: 25997442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
    Geyer J; Bogan R
    Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.